AxoGen, Inc. Receives David J. Gury Company of the Year Award from BioFlorida
October 18 2017 - 7:00AM
AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and
marketing innovative surgical solutions for peripheral nerve
injuries, has received the BioFlorida David J. Gury Company of the
Year Award. The award, presented this week at the 20th anniversary
BioFlorida Annual Conference, recognizes a company that has
achieved significant milestones and has contributed to the growth
of Florida's life sciences industry.
“Our platform for nerve repair can play an
important role in helping surgeons improve the quality of life for
patients with nerve damage,” said Karen Zaderej, president and CEO
of AxoGen. “AxoGen has successfully evolved, expanding laterally
from an initial niche product in a new market to a comprehensive
nerve repair platform in an emerging market. We are grateful for
the partnerships we have enjoyed on this journey; the University of
Florida, the communities of Gainesville and Alachua, BioFlorida,
and many others have provided support as we built a growing and
sustainable life sciences business.”
AxoGen, founded in Alachua, FL in 2002 with
technology licensed from the University of Florida, is the leading
company focused specifically on the science, development, and
commercialization of technologies for peripheral nerve regeneration
and repair. AxoGen is redefining the way damaged peripheral nerves
are repaired by developing new nerve repair products and expanded
applications that bring meaningful solutions to current clinical
challenges.
Under the leadership of Karen Zaderej, AxoGen has
experienced 26 consecutive quarters of year-over-year double-digit
growth and reported a record $15.2 million in revenue in Q2 2017,
representing 46 percent growth over the prior year.
“AxoGen is a stand-out example of a Florida-based
life science company that is changing health care around the world
and inspiring our industry through ingenuity, innovation, and
compelling financial and clinical results,” said Nancy K. Bryan,
president and CEO of BioFlorida. “We are delighted to honor AxoGen
with this award and look forward to their continued success.”
BioFlorida is the voice of Florida’s life sciences
industry, representing nearly 6,000 establishments and research
organizations in the biopharmaceutical, medical technology and
bioagriculture sectors that collectively employ nearly 83,000
Floridians. The David J. Gury Company of the Year Award is named in
honor of David Gury, one of the founding directors of
BioFlorida.
About AxoGenAxoGen (AXGN) is a
global leader in innovative surgical solutions for peripheral nerve
injuries. AxoGen is the leading company focused specifically on the
science, development and commercialization of technologies for
peripheral nerve regeneration and repair. We are passionate about
restoring nerve function and quality of life to patients with
peripheral nerve injuries by providing innovative, clinically
proven and economically effective repair solutions for surgeons and
health care providers. Peripheral nerves provide the pathways for
both motor and sensory signals throughout the body. Every day,
people suffer traumatic injuries or undergo surgical procedures
that impact the function of their peripheral nerves. Damage to
a peripheral nerve can result in the loss of muscle or organ
function, the loss of sensory feeling, or the initiation of
pain.
AxoGen's platform for nerve repair features a
comprehensive portfolio of products, including Avance® Nerve Graft,
an off-the-shelf processed human nerve allograft for bridging
severed nerves without the comorbidities associated with a second
surgical site, AxoGuard® Nerve Connector, a porcine submucosa
extracellular matrix (ECM) coaptation aid for tensionless repair of
severed nerves, AxoGuard® Nerve Protector, a porcine submucosa ECM
product used to wrap and protect injured peripheral nerves and
reinforce the nerve reconstruction while preventing soft tissue
attachments, and Avive® Soft Tissue Membrane, a minimally
processed human umbilical cord membrane that may be used as a
resorbable soft tissue covering to separate tissue layers and
modulate inflammation in the surgical bed. Along with these core
surgical products, AxoGen also offers AcroVal® Neurosensory &
Motor Testing System and AxoTouch® Two-Point Discriminator. These
evaluation and measurement tools assist health care professionals
in detecting changes in sensation, assessing return of sensory,
grip, and pinch function, evaluating effective treatment
interventions, and providing feedback to patients on nerve
function. The AxoGen portfolio of products is available in the
United States, Canada, the United Kingdom, and several other
European and international countries.
Cautionary Statements Concerning
Forward-Looking Statements This Press Release contains
"forward-looking" statements as defined in the Private Securities
Litigation Reform Act of 1995. These statements are based on
management's current expectations or predictions of future
conditions, events, or results based on various assumptions and
management's estimates of trends and economic factors in the
markets in which we are active, as well as our business plans.
Words such as "expects," "anticipates," "intends," "plans,"
"believes," "seeks," "estimates," "projects," "forecasts,"
"continue," "may," "should," "will," and variations of such words
and similar expressions are intended to identify such
forward-looking statements. The forward-looking statements may
include, without limitation, statements regarding our assessment on
our internal control over financial reporting, our growth, our 2017
guidance, product development, product potential, financial
performance, sales growth, product adoption, market awareness of
our products, data validation, our visibility at and sponsorship of
conferences and educational events. The forward-looking statements
are subject to risks and uncertainties, which may cause results to
differ materially from those set forth in the statements.
Forward-looking statements in this release should be evaluated
together with the many uncertainties that affect AxoGen's business
and its market, particularly those discussed in the risk factors
and cautionary statements in AxoGen's filings with the Securities
and Exchange Commission. Forward-looking statements are not
guarantees of future performance, and actual results may differ
materially from those projected. The forward-looking statements are
representative only as of the date they are made and, except as
required by law, AxoGen assumes no responsibility to update any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contact:Annette RuzickaCorporate & Investor
Communicationsaruzicka@AxoGenInc.com763.458.4193
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Sep 2023 to Sep 2024